Martin Shkreli, chief executive of Turing Pharmaceuticals, bought the rights to the drug in America and raised the price of Daraprim from $13.50 (£8.70) to $750 (£484) straight away.

Basically, the drug helps people with weak immune systems – mainly AIDS patients, but also cancer sufferers as well. This ridiculous hike in price will leave most people skint if they can even afford it in the first place. Unsurprisingly, Shkreli came under fire for his greedy shithousery, and tried to defend himself.

He said:

This isn’t the greedy drug company trying to gouge patients, it is us trying to stay in business. This is still one of the smallest pharmaceutical products in the world. It really doesn’t make sense to get any criticism for this.

Yeah it does, dickhead.

Anyway, it turns out him and his company have lost a shitload of money. Recent financial reports show it’s in fact a loss of $14.6 million (£9.6 million) for the quarter. What a shame, it couldn’t happen to a nicer bloke.